Staphylococcus epidermidis

Antibiotic
% Susceptible
2010
% Susceptible
2012
% Susceptible
2014
% Susceptible
2016
% Susceptible
2018
Ampicillin
+-*
+-* +-* 0 0
Azithromycin
+-*
+-*
+-*
+-* +-*
Aztreonam
-
-
-
- -
Cefazolin
+/-
+/-
+/-
+/- +/-
Cefepime
+/-
+/-
+/-
+/- +/-
Ceftazidime
+/-
+/-
+/-
+/- +/-
Ceftriaxone
43
47
54
48 52
Cefuroxime
+/-
+/-
+/-
+/- +/-
Ciprofloxacin
53
60
61
56 61
Clarithromycin
+-*
+-*
+-*
+-* +-*
Clindamycin
63
62
61
46 64
Doxycycline
83
81
86
85 83
Erythromycin
35
30
32
19 37
Gentamicin
89
90
89
89 90
Imipenem
+-*
+-*
+-*
+-* +-*
Levofloxacin 50 60 61 57 61
Meropenem +-* +-* +-* +-* +-*
Moxifloxacin 63 75 +/- 73 82
Nitrofurantoin 99& 99& 99& 99& 99&
Oxacillin/Naf 43 47 54 48 53
Penicillin 2 0 - 0 0
Piperacillin +/- +/- +/- +/- +/-
Piperacillin/tazo +-* +-* +-* +-* +-*
Ticarcillin/Clav +-* +-* +-* +-* +-*
Tobramycin +/- +/- +/- +/- +/-
TMP/SMX 59 56 56 54 59
Unasyn/Aug 43 47 54 48 53
Vancomycin 100 100 100 100 100
       
# Tested 386 551 402 468 436

Comments:  

 

Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections